Patel Jinali R, Ranjan Sinthu S, Wasserman Barry N
aWills Eye Hospital, Philadelphia, Pennsylvania, USA bRutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Curr Opin Ophthalmol. 2016 Sep;27(5):387-92. doi: 10.1097/ICU.0000000000000286.
To review the most recent literature regarding the clinical experience of antivascular endothelial growth factor (anti-VEGF) therapies in the treatment of retinopathy of prematurity (ROP).
Anti-VEGF agents in stage 3+ and aggressive posterior ROP have been shown to induce rapid ROP regression. However, significant reoccurrence rates can require repeat injections and thus longer term and more frequent follow-up. Initial studies reflect conflicting evidence regarding significant systemic side effects of these treatments, and outcomes in these patients past the first few years of life are yet to be definitively determined.
Although anti-VEGF therapies show promise in the treatment of ROP, frequent reoccurrences and lack of thorough data about long-term side effects of pharmacologic intervention necessitate further research before anti-VEGF agents become the mainstay of ROP management.
回顾关于抗血管内皮生长因子（anti-VEGF）疗法治疗早产儿视网膜病变（ROP）临床经验的最新文献。
抗VEGF药物已被证明可使3期以上及侵袭性后部ROP迅速消退。然而，较高的复发率可能需要重复注射，因此需要更长期且更频繁的随访。初步研究关于这些治疗的显著全身副作用的证据相互矛盾，这些患者在生命最初几年后的结局尚未明确确定。
尽管抗VEGF疗法在ROP治疗中显示出前景，但频繁复发以及缺乏关于药物干预长期副作用的全面数据，使得在抗VEGF药物成为ROP治疗的主要手段之前，有必要进一步研究。
